Insulet Corporation

Equities

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 20:00:00 10/03/2026 GMT			5-day change	1st Jan Change
238.24 ^USD	-0.89%		-1.49%	-16.18%

03-10	Insulet Corporation Presents Evolution 2 Results and Demonstrates Omnipod Fully Closed-Loop System for Adults with Type 2 Diabetes	CI
02-23	Insulet Insider Bought Shares Worth $1,029,205, According to a Recent SEC Filing	MT

Insulet Launches Omnipod® 5 and Omnipod Discover? in the Middle East to Transform Diabetes Care

Published on 02/05/2026 at 04:22 pm GMT

S&P Capital IQ

INSULET CORPORATION

-0.89%

S&P GCC COMPOSITE PRICE (USD)

+0.34%

DEXCOM, INC.

-1.38%

FTSE KUWAIT INDEX

-0.06%

S&P QATAR LARGEMIDCAP INDEX NTR

-1.55%

Insulet Corporation announced its transformative Omnipod 5 Automated Insulin Delivery (AID) System is now available in the Middle East - including Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates (UAE). The Company is making the announcement at the 16th edition of the Emirates Diabetes and Endocrine Congress (EDEC) in Dubai. The Omnipod 5 System simplifies diabetes management and has demonstrated strong glycemic outcomes, including improved time in range and lowering HbA1c, by automatically adjusting insulin delivery every five minutes and eliminating the need for multiple daily injections (MDI)2. The waterproof3, discreet, and wearable Omnipod 5 is the first tubeless AID system that communicates with a sensor and proactively corrects for highs and helps to protect against lows, day and night4,5. Omnipod 5 is indicated for individuals aged two years and older with type 1 diabetes and compatible with the Abbott FreeStyle Libre 2 Plus sensor and the Dexcom G7 sensor in Saudi Arabia, Kuwait, and the UAE, and with the Dexcom G 7 sensor in Qatar.

Omnipod Discover: Diabetes Data Management - Simplified: Insulet is also launching Omnipod Discover, a proprietary and retrospective data analytics and reporting platform designed for Omnipod 5 users, their caregivers, and healthcare providers. Easy to access, Omnipod Discover streamlines the analysis of glucose and insulin delivery data and delivers meaningful insights -- transforming complex information into clear, relevant trends and recommendations that inform diabetes management. Its web-based intuitive display shows how the Omnipod 5 algorithm automates insulin delivery, enabling understanding of trends to make decisions confidently.

Users can also access their data with insights in a simplified way that empowers them to understand and manage their diabetes. Omnipod Discover is being introduced in these Middle Eastern markets first, with plans to expand to other countries where Omnipod 5 is available. With these new market launches, Omnipod 5 is now available globally in 19 countries with plans to launch in Spain (a new market for Insulet) in 2026, followed by Greece and Croatia in the first half of 2027.

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
INSULET CORPORATION	238.24USD	-0.89%	-1.49%	16.77B
S&P GCC COMPOSITE PRICE (USD)	151.69PTS	+0.34%	+0.72%	-
DEXCOM, INC.	67.79USD	-1.38%	-7.24%	26.09B
FTSE KUWAIT INDEX	595.25PTS	-0.06%	+2.06%	-
S&P QATAR LARGEMIDCAP INDEX NTR	387.38PTS	-1.55%	+1.03%	-

Latest news about Insulet Corporation

03-10	Insulet Corporation Presents Evolution 2 Results and Demonstrates Omnipod Fully Closed-Loop System for Adults with Type 2 Diabetes	CI
02-23	Insulet Insider Bought Shares Worth $1,029,205, According to a Recent SEC Filing	MT
02-19	Goldman Sachs Adjusts Insulet Price Target to $326 From $363, Maintains Buy Rating	MT
02-19	Canaccord Genuity Adjusts Insulet PT to $435 From $450, Maintains Buy Rating	MT
02-19	Raymond James Adjusts Insulet Price Target to $355 From $385, Maintains Outperform Rating	MT
02-19	Leerink Partners Adjusts Insulet Price Target to $360 From $386, Maintains Outperform Rating	MT
02-19	Bernstein Adjusts Insulet Price Target to $330 From $380, Maintains Outperform Rating	MT
02-19	JPMorgan Adjusts Insulet Price Target to $340 From $415, Maintains Overweight Rating	MT
02-19	Barclays Adjusts Insulet Price Target to $286 From $274, Maintains Underweight Rating	MT
02-19	Truist Adjusts Price Target on Insulet to $360 From $390, Maintains Buy Rating	MT
02-19	Oppenheimer Lowers Price Target on Insulet to $300 From $365, Maintains Outperform Rating	MT
02-18	Insulet Shares Rise After Q4 Results Beat	MT
02-18	Insulet Corporation, Q4 2025 Earnings Call, Feb 18, 2026
02-18	Insulet Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-18	Sector Update: Health Care	MT

Chart Insulet Corporation

Duration

Period

PODD: Dynamic Chart

Company Profile

Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.

Employees

5,400

Sector

Medical Equipment, Supplies & Distribution

More about the company